Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company ...

Note: not an actual photo of Robin A personalised central serous chorioretinopathy treatment by London consultant ophthalmi ...

China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

Discover how rising healthcare spending can be turned into income growth. Build a retirement portfolio that thrives in a key ...